Abstract
Introduction
Sinonasal teratocarcinosarcoma (SNTCS) is an exceedingly rare malignant neoplasm of the paranasal sinuses. This tumor possesses the histopathologic features of both teratomas and carcinosarcomas. Its morphologic variations and similarities to other types of soft-tissue sarcomas pose a diagnostic challenge. Moreover, inadequate tumor sampling or a lack of awareness of this entity may lead to an erroneous diagnosis.
Since the first description of an SNTCS in 1983, 1 only about 100 cases have been reported in the world literature. The treatment for SNTCS is wide excision with adjuvant chemotherapy and irradiation. Despite timely treatment, the overall prognosis is poor.
We report a new case of SNTCS-one that involved intracranial extension-and we describe its presentation, treatment, and histopathologic features.
Case report
A 58-year-old white man presented to an outside institution with a 1-year history of nasal obstruction and intermittent bouts of epistaxis following unsuccessful medical management with decongestants and antihistamines. The patient also had noticed a gradually enlarging leftsided nasal mass that extended to the nostril opening. He subsequently underwent endoscopic sinus surgery (ESS), and the pathology report identified the surgical specimen as an SNTCS with grossly positive margins. The patient was then referred to our institution for further evaluation and treatment.
On presentation to our clinic, the patient denied vision changes, diplopia, left-sided epiphora, unilateral rhinorrhea, cheek numbness, radiating ear pain, dysphagia, odynophagia, weight loss, fever, chills, night sweats, or any other constitutional symptom. His medical and surgical histories were remarkable only for his recent ESS. His family history and a review of symptoms were noncontributory. He did not smoke tobacco but occasionally drank alcohol.
On physical examination, the patient was well developed and appeared to be his stated age. Nasal endoscopy demonstrated a nasal cavity status post ESS without any obvious or suspicious nasal mucosal lesion. Neck palpation revealed no lymphadenopathy or thyroid mass. The cranial nerves were grossly intact. Findings on the remainder of the otolaryngologic examination were within normal limits.
Computed tomography (CT) of the facial bones revealed extensive opacification throughout the left ostiomeatal complex, the middle and anterior left nasal air cavity, and the anterior portions of the ethmoid sinuses; the opacification extended to the level of the nares (figure 1).
Magnetic resonance imaging (MRI) demonstrated a contrast-enhancing mass within the anterior ethmoid air cells on the left, with a small amount of intracranial extension through the cribriform plate (figure 2).
Co-registered positron-emission tomography/computed tomography (PET/CT) with F18-fluorodeoxyglucose (FDG) showed a mild uptake of FDG in the left ethmoid sinus; it did not show any other abnormal FDG uptake elsewhere in the body.
The case was presented at our institution's multidisciplinary head and neck tumor conference. The patient subsequently underwent anterior craniofacial resection and wide excision of locally involved dura. Intraoperative findings included obvious tumor extension through the left cribriform plate into the anterior cranial vault without gross intraparenchymal extension. Frozen sections of all surgical margins were negative, findings that were later confirmed on final pathology. There were no apparent intraoperative complications.
The patient was observed for 2 days postoperatively in the intensive care unit, where he remained stable. A follow-up CT was unremarkable. He was discharged home on postoperative day 5. He underwent postoperative chemotherapy and irradiation, and he was alive and doing well at 48 months of follow-up.
Histopathologic examination identified the excised mass as a malignant neoplasm with variant histomorphology. There was abundant neuroepithelium composed of small cells with inconspicuous nucleoli and scant eosinophilic fibrillary cytoplasm arranged in nests and occasional rosettes ( figure 3, A) . These cells exhibited frequent apoptosis and mitoses. Intermingled was an abundant spindled stroma that varied from blandappearing fibroblasts to spindle cells with malignant cytologic features. Nests of squamous epithelium with prominent cytoplasmic clearing in addition to foci of malignant columnar epithelium consistent with an adenocarcinoma were also identified ( figure 3, B) .
Immunohistochemical staining showed focal positivity in the primitive neuroepithelial component for chromogranin, neuron-specific enolase, synaptophysin, and CD56. There was also patchy positivity for cytokeratin and p16 staining in the (neuro)epithelial components. These findings indicated a malignant neoplasm with carcinomatous, sarcomatous, and neuroepithelial differentiation, which were most consistent with SNTCS.
Discussion
In 1983, Shanmugaratnam et al described the first reported case of SNTCS as a teratoid carcinosarcoma. On histopathology, SNTCSs contain a combination of benign and malignant epithelial, mesenchymal, and teratoid elements. They exhibit a heterogenic architectural growth pattern that features a diversity of tissue types with varying degrees of maturity. 3 The epithelial component is usually represented by "fetal-appearing" keratinizing or nonkeratinizing squamous epithelium, neuroendocrine elements, and glandular structures lined with either cuboidal or columnar cells. The mesenchymal component is represented by immature cartilage, chondroid areas, smooth muscle, osteoid, and fibrovascular tissue. [4] [5] [6] [7] [8] The teratoid component is represented by organoid structures. Foci of seminoma, germinoma, choriocarcinoma, and embryonal carcinoma are not present. 4, 6 Because these tumors are very heterogeneous in nature, poor sampling technique often leads to misdiagnosis. 2, 7, 9 SNTCSs usually arise from the nasal cavities and paranasal sinuses. In decreasing order of prevalence, SNTCSs are also found in the orbit, skull base, cribriform plate, nasopharynx, and anterior cranial fossa. 7, [10] [11] [12] Most cases of SNTCS are characterized by extension to adjacent structures at the time of presentation.
The histogenesis of SNTCS is still unclear. It has been suggested that a primitive cell in the olfactory membrane is a precursor of SNTCS; this hypothesis is based on the resemblance of SNTCS to olfactory neuroblastoma and the frequent presence of neuroectodermal tissue. 2 Despite the fact that SNTCSs do not contain elements of either yolk sac tumor, germinoma, choriocarcinoma, or embryonal carcinoma, 2,5,13,14 some authors 1,2,15 have postulated that they arise from germ cells or neural crests. It has also been postulated that nonspecific primitive cells that are capable of differentiation in an organized yet divergent way may give rise to SNTCS. 14 The most common presenting signs of SNTCS are nasal obstruction and epistaxis. 5, 6 Other manifestations, which are usually related to the degree of tumor extension, can include headache, dizziness, focal neurologic deficits secondary to direct tumor extension, eye and/ or facial pain, expectoration of tissue, epiphora, vision loss, exophthalmos, and anosmia. 6 Nasal examination will reveal a moderately firm, red or reddish-purple mass with friable and necrotic areas. 7 Radiologic features are nonspecific, and they vary according to the involved site.
An accurate diagnosis requires adequate diagnostic specimens and experience with these entities. The differential diagnosis of SNTCS includes olfactory neuroblastoma, neuroendocrine carcinoma/small-cell carcinoma, sinonasal undifferentiated carcinoma, squamous cell carcinoma, malignant salivary-gland-type tumors, adenocarcinoma, and metastatic teratoma. 5 The optimal treatment of SNTCS has not been clearly defined because of the small number of cases. Because this is a rapidly growing malignancy, an aggressive multimodal therapeutic approach should always be considered. Combining radiotherapy and/or chemotherapy with wide surgical excision might optimize the outcome. 16, 17 Yet despite therapy, the average length of survival following diagnosis is only 1.7 years, and only 40% of patients survive beyond 3 years. 2, 18 A 37% recurrence rate has been reported in patients who have undergone surgery and postoperative irradiation. 10, 11, 15, 19, 20 The high rate of local recurrence and metastasis is suggestive of a highly aggressive biologic behavior. 16 
